SCHEMBL23106986

SCHEMBL23106986

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](N)C(=O)O)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.68
▸ NOD1 Q9Y239 12/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725211 0.98 GLP1R (0.70) GLP1RNOD1
SCHEMBL18869571 0.98 GLP1R (0.70) GLP1RNOD1
SCHEMBL15276351 0.93 NOD1 (0.71) GLP1RNOD1
SCHEMBL26076118 0.92 GLP1R (0.77) GLP1RNOD1
SCHEMBL19034936 0.90 GLP1R (0.61) GLP1RNOD1
SCHEMBL19034927 0.90 GLP1R (0.61) GLP1RNOD1
SCHEMBL19034808 0.90 GLP1R (0.61) GLP1RNOD1
SCHEMBL19034989 0.90 GLP1R (0.61) GLP1RNOD1
SCHEMBL19034933 0.90 GLP1R (0.61) GLP1RNOD1
SCHEMBL18117511 0.90 GLP1R (0.61) GLP1RNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11752190-B2 Modulators of complement activity RA PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
US-20210077572-A1 MODULATORS OF COMPLEMENT ACTIVITY UCB HOLDINGS, INC. 2021-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11752190-B2 Modulators of complement activity C3AR1, C1QBP, C5AR1 GLP1R 542/4885NOD1 1461/4885
US-20210077572-A1 MODULATORS OF COMPLEMENT ACTIVITY C3AR1, C1QBP, C5AR1 GLP1R 542/4885NOD1 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback